Portola Pharmaceuticals Inc (NASDAQ:PTLA) has been assigned an average rating of “Hold” from the eleven brokerages that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $45.20.
Several equities analysts recently commented on PTLA shares. Oppenheimer set a $42.00 target price on Portola Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, April 12th. Credit Suisse Group started coverage on LTC Properties in a research note on Wednesday. They issued an “underperform” rating and a $19.00 target price for the company. Zacks Investment Research lowered Hersha Hospitality Trust from a “buy” rating to a “hold” rating in a research note on Thursday, May 2nd. BidaskClub lowered ZIX from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, May 21st. Finally, Cowen reiterated a “buy” rating and issued a $149.00 target price on shares of Intercept Pharmaceuticals in a research note on Wednesday, May 8th.
Shares of NASDAQ PTLA traded down $0.09 during trading on Friday, reaching $26.07. The company had a trading volume of 872,019 shares, compared to its average volume of 899,145. Portola Pharmaceuticals has a twelve month low of $14.81 and a twelve month high of $42.17. The stock has a market capitalization of $1.78 billion, a PE ratio of -5.20 and a beta of 2.22. The business’s 50-day simple moving average is $27.24. The company has a quick ratio of 4.77, a current ratio of 4.81 and a debt-to-equity ratio of 5.15.
In other news, Director Hollings Renton sold 5,000 shares of the stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $34.45, for a total transaction of $172,250.00. Following the sale, the director now directly owns 14,000 shares in the company, valued at approximately $482,300. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.50% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the business. Icon Wealth Partners LLC bought a new position in Portola Pharmaceuticals during the first quarter worth about $26,000. FTB Advisors Inc. bought a new position in Portola Pharmaceuticals during the first quarter worth about $33,000. Cornerstone Advisors Inc. bought a new position in Portola Pharmaceuticals during the first quarter worth about $46,000. Bank of Montreal Can lifted its stake in Portola Pharmaceuticals by 50.7% during the first quarter. Bank of Montreal Can now owns 3,323 shares of the biopharmaceutical company’s stock worth $115,000 after purchasing an additional 1,118 shares during the period. Finally, Parallel Advisors LLC lifted its stake in Portola Pharmaceuticals by 24.2% during the first quarter. Parallel Advisors LLC now owns 5,766 shares of the biopharmaceutical company’s stock worth $200,000 after purchasing an additional 1,125 shares during the period.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.
See Also: Is a Roth IRA right for you?
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.